Kathari Yamini K, An Max, Dougherty Christine, Emadi Ashkan
Departments of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.
Pharmaceuticals (Basel). 2024 Mar 5;17(3):335. doi: 10.3390/ph17030335.
Older adults who are diagnosed with acute lymphoblastic leukemia (ALL) and are treated with chemotherapy generally have poor outcomes. Blinatumomab is a CD19/CD3 bispecific T-cell engager that has been approved for the treatment of B-cell ALL in the relapsed/refractory setting or in patients with minimal residual disease (MRD) positivity. We previously reported on a small cohort of older adults with newly diagnosed Philadelphia chromosome negative B-cell ALL who were treated with blinatumomab monotherapy in the first line setting. This is a long-term follow up of those patients and their clinical courses. All five patients achieved complete remission (CR) after one cycle of blinatumomab, and three were MRD-negative. Two patients completed three cycles of blinatumomab, two patients completed four cycles of blinatumomab, and one patient completed 17 cycles of blinatumomab total. In the last four years, four of these patients had relapsed disease requiring additional therapy. Two patients are alive after 61 months and 57 months since their first cycle of blinatumomab. Two of the patients died at 10 months and one died at 20 months. Here we describe the long-term clinical courses of these patients.
被诊断为急性淋巴细胞白血病（ALL）并接受化疗的老年患者通常预后较差。博纳吐单抗是一种CD19/CD3双特异性T细胞衔接器，已被批准用于治疗复发/难治性环境或微小残留病（MRD）阳性患者的B细胞ALL。我们之前报道过一小群新诊断为费城染色体阴性B细胞ALL的老年患者，他们在一线治疗中接受了博纳吐单抗单药治疗。这是对这些患者及其临床病程的长期随访。所有五名患者在接受一个周期的博纳吐单抗治疗后均实现完全缓解（CR），其中三名患者MRD呈阴性。两名患者完成了三个周期的博纳吐单抗治疗，两名患者完成了四个周期的博纳吐单抗治疗，一名患者总共完成了17个周期的博纳吐单抗治疗。在过去四年中，这些患者中有四名出现疾病复发，需要额外治疗。两名患者在接受第一个周期的博纳吐单抗治疗后的61个月和57个月后仍存活。两名患者分别在10个月和20个月时死亡。在此，我们描述这些患者的长期临床病程。
